The AI Molecule

Advanced Technology, Article, Artificial Intelligence, biotechnology, Life Sciences, Science, Software, Transformative Businesses, , , , , , , , ,

Artificial intelligence is reducing the time and cost required to discover new drug candidates. New forms of late-stage capital are allowing better companies to stay independent longer. Direct-to-patient distribution is weakening Pharma’s control of the commercial channel. Together, these changes alter the architecture of biotechnology. The molecule is being separated from the old machine that used to deliver it. This is a structural change in how drugs are discovered, financed, developed, negotiated, and delivered. Biotech companies will build discovery systems, develop clinical evidence, control proprietary data, preserve financing options, and reach patients more directly.

Time for Hard Things

Advanced Technology, Article, Artificial Intelligence, Book Chapter, Hard Tech, Transformative Businesses, , , , , , ,

With better models, more effective benchmarks, and a framework for constant improvement, now is the time to focus AI on complex, innovative, and transformational tasks. Essentially, AI and models should focus on hard tech. Hard tech refers to businesses rooted in advanced engineering and scientific innovation, often involving the development of physical products or systems that address complex challenges. Beyond drones, robots, and AI-driven hardware, the following are prominent examples of hard tech opportunities across industries. AI-driven hard tech is creating new business models and industries, such as personalized medicine, autonomous logistics, smart infrastructure, and agentic AI platforms that autonomously manage complex operations, reshaping the competitive landscape and unlocking new avenues for value creation. As a result, businesses and professionals who embrace interdisciplinary skills and continuous learning will thrive in the hard tech ecosystem.